Chiang C H, Ho J I, Chen J L
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China.
J Ocul Pharmacol Ther. 1996 Winter;12(4):471-80. doi: 10.1089/jop.1996.12.471.
Two timolol preparations, a gel and an eyedrop with a thickening agent, and one commercial eyedrop without a thickening agent, were studied in rabbits. After topical administration of these three preparations in rabbits, aqueous humor was withdrawn and the proteins removed from the samples by precipitation with acetonitrile. Timolol concentrations were determined directly by an HPLC method. The HPLC mobile phase was composed of methanol and 5 mM d-camphorsulfonic acid (in 1% acetic acid) with a ratio of 49:51 (v/v). A reversed phase C18 column was used to separate samples with a flow rate of 0.8 mL/min and a UV detector set at 284 nm. A two-compartment pharmacokinetic model was used to fit the aqueous humor level for determining the drainage (kd) and absorption rate constants (ka) in the precorneal area as well as the elimination rate constant (ke) of timolol in aqueous humor. For ka +kd, the eyedrop without a thickening agent had the highest value (0.160 min-1), followed by the eyedrop with a thickening agent (0.030 min-1), and the gel had the lowest value (0.009 min-1). It suggests that the gel has a longer retention time in eyes to improve ocular bioavailability and decrease side effects. The AUC0 approximately infinity for the aqueous humor profile with time coordinates were 4142, 2974, and 1604 micrograms min/mL, for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent, respectively. In another study, timolol preparations were also topically administered in alpha-chymotrypsin-induced glaucoma rabbits for determining the lowering effect on intraocular pressure (IOP). The durations of depressing IOP for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent were 24, 14 and 10 hrs, respectively. Thus, the gel preparation has a longer duration and a higher ocular bioavailability which might be further developed in the treatment of open-angle glaucoma.
在兔子身上研究了两种噻吗洛尔制剂,一种凝胶剂和一种含增稠剂的滴眼液,以及一种不含增稠剂的市售滴眼液。在兔子局部应用这三种制剂后,抽取房水,并用乙腈沉淀从样品中去除蛋白质。噻吗洛尔浓度通过高效液相色谱法直接测定。高效液相色谱流动相由甲醇和5 mM d-樟脑磺酸(在1%乙酸中)组成,比例为49:51(v/v)。使用反相C18柱分离样品,流速为0.8 mL/min,紫外检测器设置在284 nm。采用二室药代动力学模型拟合房水水平,以确定角膜前区域的引流(kd)和吸收速率常数(ka)以及房水中噻吗洛尔的消除速率常数(ke)。对于ka+kd,不含增稠剂的滴眼液值最高(0.160 min-1),其次是含增稠剂的滴眼液(0.030 min-1),凝胶剂值最低(0.009 min-1)。这表明凝胶剂在眼中的保留时间更长,可提高眼部生物利用度并减少副作用。凝胶剂、含增稠剂的滴眼液和不含增稠剂的滴眼液,其房水浓度-时间曲线的AUC0至无穷大分别为4142、2974和1604微克·分钟/毫升。在另一项研究中,噻吗洛尔制剂也局部应用于α-糜蛋白酶诱导的青光眼兔子,以确定其对眼压(IOP)的降低作用。凝胶剂、含增稠剂的滴眼液和不含增稠剂的滴眼液降低眼压的持续时间分别为24、14和10小时。因此,凝胶剂制剂具有更长的持续时间和更高的眼部生物利用度,在开角型青光眼治疗中可能会得到进一步开发。